S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Did You See These Trend Reversals? (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$9.16
+0.64 (+7.51%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.57
▼
$9.28
50-Day Range
$6.99
▼
$9.95
52-Week Range
$1.05
▼
$10.20
Volume
2.20 million shs
Average Volume
394,118 shs
Market Capitalization
$565.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.14

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
32.6% Upside
$12.14 Price Target
Short Interest
Bearish
6.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Avadel Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to $0.08 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

752nd out of 1,004 stocks

Pharmaceutical Preparations Industry

371st out of 489 stocks

See Top Rated MarketRank™ Stocks Here

AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

April 1, 2023 | markets.businessinsider.com
LifeSci Capital Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
March 31, 2023 | markets.businessinsider.com
Jefferies Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
April 1, 2023 | Investorplace Media (Ad)
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
March 31, 2023 | americanbankingnews.com
Avadel Pharmaceuticals (NASDAQ:AVDL) Trading Down 2.6%
March 30, 2023 | finanznachrichten.de
Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
March 30, 2023 | msn.com
Earnings Scheduled For March 30, 2023
March 30, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 30, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
April 1, 2023 | Investorplace Media (Ad)
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
March 30, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
March 30, 2023 | finance.yahoo.com
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
March 29, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
March 29, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares
March 29, 2023 | americanbankingnews.com
Brokerages Set Avadel Pharmaceuticals plc (NASDAQ:AVDL) Price Target at $12.14
March 28, 2023 | americanbankingnews.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL) to Post FY2023 Earnings of ($1.42) Per Share, HC Wainwright Forecasts
March 26, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Avadel Pharmaceuticals (AVDL), CVRx (CVRX)
March 24, 2023 | americanbankingnews.com
HC Wainwright Weighs in on Avadel Pharmaceuticals plc's FY2024 Earnings (NASDAQ:AVDL)
March 24, 2023 | americanbankingnews.com
Avadel Pharmaceuticals (NASDAQ:AVDL) Given New $14.00 Price Target at HC Wainwright
March 22, 2023 | marketwatch.com
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ(TM) Ahead of Anticipated Final Approval Decision
March 22, 2023 | markets.businessinsider.com
Avadel Pharma Says FDA Approves Pre-Launch Activities Importation Requests For LUMRYZ
March 22, 2023 | msn.com
Avadel stock rises on FDA nod to import sleep disorder drug Lumryz ahead of potential approval
March 22, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
March 18, 2023 | money.usnews.com
Avadel Pharmaceuticals plc - ADR
March 14, 2023 | seekingalpha.com
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz
March 2, 2023 | markets.businessinsider.com
Avadel Seeks Final FDA Approval For Lumryz For Treatment Of Cataplexy In Adults With Narcolepsy
March 2, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension
February 28, 2023 | finance.yahoo.com
Avadel Pharmaceuticals Shows Big Promise -- And Risk
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
11/08/2021
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
CUSIP
N/A
CIK
1012477
Web
www.avadel.com
Phone
(531) 901-5201
Fax
353-1526-1077
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$12.14
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+32.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-77,330,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-334.88%
Return on Assets
-51.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.73
Quick Ratio
2.73

Sales & Book Value

Annual Sales
$22.33 million
Price / Sales
25.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
6.89

Miscellaneous

Outstanding Shares
61,780,000
Free Float
59,802,000
Market Cap
$565.90 million
Optionable
Optionable
Beta
1.49

Social Links


Key Executives

  • Gregory J. Divis
    Chief Executive Officer & Director
  • Scott Macke
    Vice President-Supply Chain & Operations
  • Thomas S. McHugh
    Chief Financial Officer & Senior Vice President
  • Jason Vaughn
    Senior Vice President-Technical Operations
  • Jennifer Gudeman
    Vice President-Medical & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2023?

7 equities research analysts have issued 12 month price objectives for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $12.14 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.

How have AVDL shares performed in 2023?

Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 27.9% and is now trading at $9.16.
View the best growth stocks for 2023 here.

When is Avadel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our AVDL earnings forecast.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.38) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.38). During the same quarter in the previous year, the business posted ($0.20) earnings per share.

What ETFs hold Avadel Pharmaceuticals' stock?

ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $9.16.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $565.90 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 4/1/2023 by MarketBeat.com Staff